EcoDrugPlus

Dna Topoisomerase Ii Beta

Ensembl ID : ENSDORG00000007009
Gene Symbol: TOP2B
3 Cross references
210 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSDORG00000006453
Gene Symbol: EML4
3 Cross references
214 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSDORG00000012522
Gene Symbol: EPHA2
4 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSDORG00000003956
Gene Symbol: EPHA3
4 Cross references
216 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSDORG00000007887
Gene Symbol: EPHB4
4 Cross references
168 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSDORG00000003616
Gene Symbol: FAU
2 Cross references
229 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSDORG00000026774
Gene Symbol: FKBP1A
3 Cross references
208 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSDORG00000016706
Gene Symbol: FYN
3 Cross references
264 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSDORG00000002381
Gene Symbol: GPR119
4 Cross references
176 Possible Orthologues:

G Protein-Coupled Receptor 84

Ensembl ID : ENSDORG00000010631
Gene Symbol: GPR84
3 Cross references
124 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSDORG00000005152
Gene Symbol: HCK
3 Cross references
206 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSDORG00000010894
Gene Symbol: ITK
4 Cross references
208 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).